The interleukin-3 receptor alpha chain (IL-3Rα), more commonly referred to as CD123, is
widely overexpressed in various hematological malignancies, including acute myeloid …

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare haematological malignancy
derived from the precursors of plamacytoid dendritic cells, with an aggressive clinical course …

Background Blastic plasmacytoid dendritic-cell neoplasm (BPDCN) is an aggressive
hematologic cancer that is caused by transformed plasmacytoid dendritic cells that …

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized
by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other …

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic
malignancy with dismal outcomes for which no standard therapy exists. We found that …

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia for
which we developed a nationwide network to collect data from new cases diagnosed in …

Recent studies indicate that abnormalities of the alpha-chain of the interleukin-3 receptor (IL-
3RA or CD123) are frequently observed in some leukemic disorders and may contribute to …

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy that
can involve the bone marrow, peripheral blood, skin, lymph nodes, and the central nervous …

This is the first prospective study of treatment of patients with blastic plasmacytoid dendritic
cell neoplasm (BPDCN), an aggressive hematologic malignancy derived from plasmacytoid …

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive leukemia of
plasmacytoid dendritic cells (pDC). BPDCN occurs at least three times more frequently in …